Liver Transplant Cost in India: What the Bill Covers and How Families Pay for It

A living-donor liver transplant in India costs roughly ₹20–25 lakh — the figure Prof Mohamed Rela gave at LTSICON 2025 — against about ₹3 crore in the United States. That pays for two operations and two ICU stays, recipient and donor. Lifelong medicines, follow-up and complications come on top. Insurance, Maharashtra’s new ₹22 lakh transplant fund and central relief schemes can carry much of it, if the paperwork starts early.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai

Picture a composite of a family I meet most weeks: a 48-year-old schoolteacher from Thane with alcohol-related cirrhosis, a MELD score of 24, and a wife willing to donate part of her liver. They have a ₹5 lakh family floater, a cousin in Dubai offering to help, and no idea what the total will be. The first question is never about the operation. It is “Doctor, kitna lagega?”

I would rather answer that honestly than vaguely. This article breaks the bill into its parts, explains why one family pays far more than another for the same operation, and walks through every route to funding it. No Gleneagles price list, because packages change and a published number would be wrong within a year. Ranges, sources and dates instead.

One point first: the alternative to paying for a transplant is not “waiting” — it is a rising risk of dying while the savings go on admissions that cure nothing.

What a liver transplant bill is made of

Families imagine one operation. In India, where most transplants use a living donor, the bill is for two people, and it starts weeks before anyone enters a theatre. The recipient’s evaluation comes first: imaging, heart and lung assessment, endoscopy, infection screening, blood work. Then the donor’s work-up — blood group, liver function, CT volumetry to measure how much liver can safely be removed, a psychological interview, and the legal clearance the Transplantation of Human Organs Act requires. Both are billed whether or not the transplant eventually happens.

The operation is the largest single line: two surgical teams, anaesthesia, blood products, an ICU stay of several days for the recipient and a shorter one for the donor, then ward care for both. And then the part no estimate can fix in advance — complications. A bile leak, a hepatic artery problem, a serious infection or a return to theatre means more ICU days, and the ICU is where bills grow fastest.

Discharge does not end the spending. Tacrolimus and mycophenolate are taken for life, with blood levels checked often in the first year. A 2012 study from Kochi costed generic immunosuppression after living-donor transplant at ₹28,705 in the first month, falling to ₹8,820 a month by the end of year one — an average of ₹17,250 — and found that half of that was the tacrolimus level test, not the tablets. Year one is the costliest, and the cost tapers rather than vanishes.

Living donor or deceased donor: why the costs differ

A 2021 review in Transplantation by Kute, Ramesh and Rela estimated that 80.3% of kidney and liver transplants in India rely on living donors, and that a liver transplant cost roughly USD 15,000–20,000 in a public hospital against USD 30,000–40,000 in the private sector. That public–private gap matters more than the choice of donor type.

Within one hospital the two routes trade costs. A living-donor transplant adds a second operation and a second hospital stay, and because the donor cannot be paid under Indian law, the recipient’s family bears the donor’s bill. What it buys is timing — a scheduled date, an optimised recipient — and a liver of known quality.

A deceased-donor transplant removes the donor surgery but adds organ retrieval and transport, and it arrives without notice — often when the patient is sicker, which means a longer ICU stay afterwards. The wait through the state allocation system is unpredictable. For a patient with a willing, suitable family donor I almost always advise the living-donor route.

What makes one family’s bill twice another’s

The honest answer is: how sick the patient is on the day of surgery.

A 2023 series from Hyderabad in Hepatology International followed 73 patients with acute-on-chronic liver failure listed for living-donor transplant. Eighteen died within 30 days of listing. The 55 who reached surgery had each needed a median of two admissions totalling 17 days beforehand, and their families had spent a median of ₹8,25,090 — range ₹26,000 to over ₹43 lakh — simply to stabilise the patient for the operation. Survival after transplant was 72.7%, and 58% had a complication in the first year. That is the economics of a rescue transplant from the ICU.

Compare the elective patient: listed early, nourished, infection-free, operated on a planned date. Shorter ICU, fewer complications, fewer readmissions. A sarcopenic patient recovers slowly, and slow recovery is billed by the day.

The lesson is uncomfortable. The cheapest transplant is the one done before the first ICU admission. If you have cirrhosis and transplant has been mentioned even in passing, the financial planning starts then, not after the first bleed. In acute liver failure, where there is no time to plan, the same funding routes must be worked in parallel within days.

Health insurance: what it covers and what it quietly does not

A retail health policy will generally cover the recipient’s hospitalisation as inpatient treatment, up to the sum insured and subject to room-rent caps and sub-limits. A ₹5 lakh floater therefore pays a fraction; a ₹25–50 lakh cover, or a base policy with a super top-up, changes the picture. Corporate group policies often carry no pre-existing-disease waiting period, which makes them unusually useful.

The donor is the grey area. I read the full text of IRDAI’s Master Circular on Health Insurance dated 29 May 2024; it contains no clause on organ-donor expenses. Whether the donor’s work-up, surgery, stay and — importantly — any donor complication are covered depends entirely on your policy wording — inbuilt and capped, an add-on, or excluded. Find the clause and get the TPA’s confirmation in writing before admission.

Cirrhosis diagnosed before you bought the policy is a pre-existing disease, and the waiting period applies. Once insured, the 2024 circular protects you: renewal cannot be refused except for established fraud or non-disclosure, nor because you claimed, and the insurer may not re-underwrite you at renewal unless you ask for a higher sum insured — so never let a policy lapse. The gap after transplant is real, though: an August 2025 report in The South First described recipients, and their donors, being refused new policies. Home medicines are not covered without an OPD benefit.

NRI families: overseas or employer policies sometimes cover treatment in India — get written pre-authorisation before the patient travels.

Government schemes and relief funds — what is actually on offer

This is where most families leave money on the table, usually because nobody told them to apply in the first week.

Ayushman Bharat PM-JAY. ₹5 lakh a year per entitled family for secondary and tertiary hospitalisation across 1,949 procedures in 27 specialties, and since September 2024 every citizen aged 70 and above gets the same cover regardless of income (Ministry of Health, PIB, 23 September 2024). Whether a liver transplant package sits in your state’s list, and at what rate, varies. In Maharashtra the real value of PM-JAY is as the gateway to the next scheme.

Maharashtra’s transplant fund (MJPJAY/PM-JAY). In September 2025 the state cabinet approved a reserve fund — 20% of claim settlements under the Mahatma Jyotirao Phule Jan Arogya Yojana and PM-JAY, managed by the State Health Assurance Society — for nine high-cost treatments beyond the ₹5 lakh ceiling, with liver transplant capped at ₹22 lakh (PTI, 23 September 2025). A Government Resolution in April 2026 put it into operation: Maharashtra residents with ration card and Aadhaar, cashless, money paid directly to the empanelled hospital, a sanctioning committee every Friday (Medical Dialogues, 14 April 2026). The hospital’s Arogya Mitra desk files it.

Rashtriya Arogya Nidhi (Union Health Ministry). One-time assistance for AAY/PHH ration-card holders and PM-JAY beneficiaries with life-threatening heart, kidney or liver disease, at government super-speciality hospitals only — up to ₹15 lakh according to the AIIMS Bhubaneswar scheme page.

Relief funds. The PMNRF site says it “assists partially to defray the expenses for medical treatment like heart surgery, kidney transplantation, cancer treatment of needy people” — partial, discretionary, liver transplant not named, applied for through the PMO with the hospital’s estimate. Maharashtra’s CM Relief Fund has historically assisted liver transplants; confirm the current ceiling with the Mantralaya cell.

Government employees should ask their own department: CGHS, ECHS, ESIC and state schemes often have transplant provisions.

Hospital help, charity, crowdfunding, loans — and what delay costs

Every transplant centre has a financial counsellor. Use them on day one. Ask for an itemised estimate in writing and ask exactly what it excludes: the donor’s bill, extra ICU days, blood products, a second operation, early readmission. Most disputes I have seen over transplant bills were not about the surgery; they were about what the family assumed was included.

Charitable trusts, community organisations and CSR funds do support transplants, and they are slow — start them alongside the scheme applications. Crowdfunding has paid for real transplants in this city; read the fee and payout terms, and never let the campaign timetable set the surgical one. A loan is a reasonable bridge for a shortfall of a few lakh and a poor way to fund the whole bill, because EMIs continue through months when neither patient nor caregiver is earning.

Which brings me to the cost that never appears on an estimate. In the landmark 2005 analysis of 12,996 adults on the American waiting list, transplant recipients had a 79% lower risk of death than comparable patients who stayed on the list. The benefit scaled with sickness — 38% lower at MELD 18–20, 96% lower at MELD 40 — and below MELD 15 there was none in the first year, which is why we do not transplant too early either. Between those points, every month of delay is paid twice: in risk, and in admissions for ascites, bleeding, encephalopathy and infection that leave the disease untouched.

So, to the composite family from Thane: get the itemised estimate this week; put the Arogya Mitra desk and your TPA to work the same day; and settle the donor question early, because a planned living-donor transplant at MELD 24 is a different operation, medically and financially, from a rescue at MELD 35. Across 1000+ transplants, about 300 of them complex, with 92% survival, the families who came through best financially were the ones who began the paperwork the week transplant was first mentioned.

References

1. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant. 2005;5(2):307–313. PMID 15643990. doi:10.1111/j.1600-6143.2004.00703.x
2. Kute VB, Ramesh V, Rela M. On the way to self-sufficiency: improving deceased organ donation in India. Transplantation. 2021;105(8):1625–1630. PMID 34291760. doi:10.1097/TP.0000000000003677
3. Sudhindran S, Aboobacker S, Menon RN, Unnikrishnan G, Sudheer OV, Dhar P. Cost and efficacy of immunosuppression using generic products following living donor liver transplantation in India. Indian J Gastroenterol. 2012;31(1):20–23. PMID 22194185. doi:10.1007/s12664-011-0138-0
4. Kulkarni AV, Reddy R, Sharma M, et al. Healthcare utilization and outcomes of living donor liver transplantation for patients with APASL-defined acute-on-chronic liver failure. Hepatol Int. 2023;17(5):1233–1240. PMID 37273169. doi:10.1007/s12072-023-10548-3
5. Ministry of Health and Family Welfare, Government of India. Transforming Healthcare: Six Years of Ayushman Bharat PM-JAY. Press Information Bureau, 23 September 2024. static.pib.gov.in (accessed 8 October 2026).
6. Press Trust of India. Maharashtra govt to fund treatment of 9 rare diseases beyond Rs 5 lakh. The Week, 23 September 2025. theweek.in (accessed 8 October 2026).
7. Medical Dialogues. Maharashtra expands cashless treatment, covers surgeries above Rs 5 lakh. 14 April 2026. medicaldialogues.in (accessed 8 October 2026).
8. Insurance Regulatory and Development Authority of India. Master Circular on IRDAI (Insurance Products) Regulations 2024 – Health Insurance. Ref IRDAI/HLT/CIR/PRO/84/5/2024, 29 May 2024. irdai.gov.in (full text consulted 8 October 2026).
9. Prime Minister’s National Relief Fund. About PMNRF. pmnrf.gov.in (accessed 8 October 2026).
10. All India Institute of Medical Sciences, Bhubaneswar. Umbrella Scheme Rashtriya Arogya Nidhi (RAN). aiimsbhubaneswar.nic.in (accessed 8 October 2026); Arthapedia, Indian Economic Service. Rashtriya Arogya Nidhi (RAN). ies.gov.in (accessed 8 October 2026).
11. The South First. Insurance woes for transplant patients in India: coverage denied. 22 August 2025. thesouthfirst.com (accessed 8 October 2026).
12. Outlook India. India emerges as global leader in living donor liver transplants amid call for public funding (LTSICON 2025). 24 November 2025. outlookindia.com (accessed 8 October 2026).
13. The Tribune. Nod to free renal, liver transplants up to Rs 3L under CM scheme (Haryana). 2 July 2024. tribuneindia.com (accessed 8 October 2026).